These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 20409441)

  • 1. Early adoption of injectable naltrexone for alcohol-use disorders: findings in the private-treatment sector.
    Abraham AJ; Roman PM
    J Stud Alcohol Drugs; 2010 May; 71(3):460-6. PubMed ID: 20409441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A longitudinal examination of alcohol pharmacotherapy adoption in substance use disorder treatment programs: patterns of sustainability and discontinuation.
    Abraham AJ; Knudsen HK; Roman PM
    J Stud Alcohol Drugs; 2011 Jul; 72(4):669-77. PubMed ID: 21683049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adoption of injectable naltrexone in U.S. substance use disorder treatment programs.
    Aletraris L; Bond Edmond M; Roman PM
    J Stud Alcohol Drugs; 2015 Jan; 76(1):143-51. PubMed ID: 25486403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using medication-assisted treatment for substance use disorders: evidence of barriers and facilitators of implementation.
    Roman PM; Abraham AJ; Knudsen HK
    Addict Behav; 2011 Jun; 36(6):584-589. PubMed ID: 21377275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The adoption of alcohol pharmacotherapies in the Clinical Trials Network: the influence of research network participation.
    Abraham AJ; Knudsen HK; Rothrauff TC; Roman PM
    J Subst Abuse Treat; 2010 Apr; 38(3):275-83. PubMed ID: 20117908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adoption and diffusion of evidence-based addiction medications in substance abuse treatment.
    Heinrich CJ; Cummings GR
    Health Serv Res; 2014 Feb; 49(1):127-52. PubMed ID: 23855719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adoption and implementation of medications in addiction treatment programs.
    Knudsen HK; Abraham AJ; Roman PM
    J Addict Med; 2011 Mar; 5(1):21-7. PubMed ID: 21359109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Organizational-level predictors of adoption across time: naltrexone in private substance-use disorders treatment centers.
    Oser CB; Roman PM
    J Stud Alcohol Drugs; 2007 Nov; 68(6):852-61. PubMed ID: 17960303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Counselor attitudes toward the use of naltrexone in substance abuse treatment: a multi-level modeling approach.
    Abraham AJ; Rieckmann T; McNulty T; Kovas AE; Roman PM
    Addict Behav; 2011 Jun; 36(6):576-583. PubMed ID: 21382667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perceptions of the state policy environment and adoption of medications in the treatment of substance use disorders.
    Knudsen HK; Abraham AJ
    Psychiatr Serv; 2012 Jan; 63(1):19-25. PubMed ID: 22227755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adherence Across FDA-Approved Medications for Alcohol Use Disorder in a Veterans Administration Population.
    Walker JR; Korte JE; McRae-Clark AL; Hartwell KJ
    J Stud Alcohol Drugs; 2019 Sep; 80(5):572-577. PubMed ID: 31603760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Very Low Frequency of Drug Therapy of Alcohol Dependence in Germany - Analysis of Data of A Statutory Health Insurance.
    Scherbaum N; Holzbach R; Stammen G; Kirchof U; Bonnet U
    Pharmacopsychiatry; 2020 Jan; 53(1):37-39. PubMed ID: 31132796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategies to increase implementation of pharmacotherapy for alcohol use disorders: a structured review of care delivery and implementation interventions.
    Williams EC; Matson TE; Harris AHS
    Addict Sci Clin Pract; 2019 Feb; 14(1):6. PubMed ID: 30744686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A categorical typology of naltrexone-adopting private substance abuse treatment centers.
    Oser CB; Roman PM
    J Subst Abuse Treat; 2008 Jun; 34(4):433-42. PubMed ID: 17997266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trends in the Use of Naltrexone for Addiction Treatment among Alcohol Use Disorder Admissions in U.S. Substance Use Treatment Facilities.
    Qeadan F; Mensah NA; Gu LY; Madden EF; Venner KL; English K
    Int J Environ Res Public Health; 2021 Aug; 18(16):. PubMed ID: 34444639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dissemination, adoption, and implementation of acamprosate for treating alcohol use disorders.
    Knudsen HK; Roman PM
    J Stud Alcohol Drugs; 2014 May; 75(3):467-75. PubMed ID: 24766759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of off-label medications in substance abuse treatment programs.
    Paino M; Aletraris L; Roman PM
    Subst Abus; 2020; 41(3):340-346. PubMed ID: 31361567
    [No Abstract]   [Full Text] [Related]  

  • 18. Adoption of naltrexone to treat alcohol dependence.
    Fuller BE; Rieckmann T; McCarty D; Smith KW; Levine H
    J Subst Abuse Treat; 2005 Apr; 28(3):273-80. PubMed ID: 15857728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multifaceted academic detailing program to increase pharmacotherapy for alcohol use disorder: interrupted time series evaluation of effectiveness.
    Harris AH; Bowe T; Hagedorn H; Nevedal A; Finlay AK; Gidwani R; Rosen C; Kay C; Christopher M
    Addict Sci Clin Pract; 2016 Sep; 11(1):15. PubMed ID: 27633982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacotherapy for alcohol dependence: perceived treatment barriers and action strategies among Veterans Health Administration service providers.
    Harris AHS; Ellerbe L; Reeder RN; Bowe T; Gordon AJ; Hagedorn H; Oliva E; Lembke A; Kivlahan D; Trafton JA
    Psychol Serv; 2013 Nov; 10(4):410-419. PubMed ID: 23356858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.